Work

CGM‐derived efficacy and overall safety of once‐weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes

Year: 2026

Type: article

Abstract: As type 2 diabetes (T2D) progresses, the addition of basal insulin to a treatment regimen is often needed to maintain glycaemic control.However, daily basal insulins, which require at least 365 injections per year, can negatively impact treatment adherence and increase the perceived burden associated with diabetes management.Onceweekly basal insulins have the potential to reduce treatment burden and positively impact adherence and glycaemic control.1,2 Insulin efsitora alfa (efsitora), a once-weekly basal insulin, has a flat pharmacokinetic (PK) profile with a peak-to-trough ratio of 1.16, similar to physiological insulin profiles.3 Efsitora also showed a consistent glucose-lowering effect across the week during a euglycaemic clamp study.Phase 3 efsitora studies demonstrated similar efficacy and safety profiles compared to the once-daily basal insulin comparators in adults with T2D.[4][5][6][7] The consistency of glucose control and safety between weekly injections of basal insulin has not been characterised for the efsitora T2D phase 3 study populations.This post-hoc analysis aimed to assess the impact of the flat efsitora PK and pharmacodynamic (PD) profiles on time in glucose range and rates of hypoglycaemia across the week, in adults with T2D. | METHODSThis post-hoc analysis assessed the glycaemic efficacy and hypoglycaemic rates across the week using data from participants treated with efsitora in three phase 3 trials in adults with T2D: QWINT-2

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.70419